Cargando…

Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors

OBJECTIVE: We compared functional impairment outcomes assessed with Sheehan Disability Scale (SDS) after treatment with duloxetine versus selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder. METHODS: Data were pooled from four randomized studies comparing treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheehan, David V., Mancini, Michele, Wang, Jianing, Berggren, Lovisa, Cao, Haijun, Dueñas, Héctor José, Yue, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049604/ https://www.ncbi.nlm.nih.gov/pubmed/26331440 http://dx.doi.org/10.1002/hup.2500

Ejemplares similares

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick, Diego, et al.
Publicado: (2016)

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
por: Hong, Jihyung, et al.
Publicado: (2015)

Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
por: Qin, Xuan, et al.
Publicado: (2022)

Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale
por: Yee, Karen S., et al.
Publicado: (2020)

Sheehan’s Syndrome Presenting as Major Depressive Disorder
por: Qadri, Mehmood I, et al.
Publicado: (2015)

Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression
por: James, Gregory M., et al.
Publicado: (2017)

Antinociceptive Effects of the Serotonin and Noradrenaline Reuptake Inhibitors Milnacipran and Duloxetine on Vincristine-Induced Neuropathic Pain Model in Mice
por: Katsuyama, Soh, et al.
Publicado: (2014)

Reliability and validity of the Sheehan disability scale modified for pathological gambling
por: Hodgins, David C
Publicado: (2013)

The Translation and Psychometric Assessment of the Persian Version of the Sheehan Disability Scale
por: Amin-Esmaeili, Masoumeh, et al.
Publicado: (2014)

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale
por: Hobart, Mary, et al.
Publicado: (2018)

The potential efficacy of serotonin noradrenaline reuptake inhibitor duloxetine in dropped head syndrome: A case report and review of the literature
por: Funao, Haruki, et al.
Publicado: (2020)

Disability during Early Pregnancy: Using the Sheehan Disability Scale during the First Trimester in Japan
por: Hada, Ayako, et al.
Publicado: (2022)

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
por: Dziurkowska, Ewelina, et al.
Publicado: (2013)

Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder
por: Keating, Charlotte, et al.
Publicado: (2013)

Psychometric evaluation of the Swedish Child Sheehan Disability Scale in adolescent psychiatric patients
por: Soler, Catalina Tores, et al.
Publicado: (2021)

Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression
por: Hieronymus, F, et al.
Publicado: (2016)

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Qin, Sisi, et al.
Publicado: (2019)

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder
por: Aldosary, Fahad, et al.
Publicado: (2021)

Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder
por: Coles, Theresa, et al.
Publicado: (2014)

The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice
por: Qin, Xuan, et al.
Publicado: (2023)

Commentary: “Consistent Superiority of Selective Serotonin Reuptake Inhibitors Over Placebo in Reducing Depressed Mood in Patients with Major Depression”
por: Fried, Eiko I., et al.
Publicado: (2015)

Clinical Utility of Semistructured Interview and Scales to Assess Withdrawal Syndromes With Dose Reduction or Discontinuation of Selective Serotonin Reuptake Inhibitors or Serotonin Norepinephrine Reuptake Inhibitors
por: Cosci, Fiammetta, et al.
Publicado: (2022)

Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
por: Atake, Kiyokazu, et al.
Publicado: (2014)

RAVE DRUG (ECSTASY) AND SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTI-DEPRESSANTS
por: Singh, A.N., et al.
Publicado: (2000)

Rapid response to selective serotonin reuptake inhibitors in post-COVID depression
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
por: Ji, Yuan, et al.
Publicado: (2012)

Effect of Selective Serotonin Reuptake Inhibitors and Immunomodulator on Cytokines Levels: An Alternative Therapy for Patients with Major Depressive Disorder
por: Hernandez, María Eugenia, et al.
Publicado: (2013)

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder
por: Martinez, James M, et al.
Publicado: (2015)

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Amare, Azmeraw T., et al.
Publicado: (2018)

Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
por: Nazarinasab, Masoumeh, et al.
Publicado: (2022)

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†
por: Montgomery, Stuart A, et al.
Publicado: (2014)

Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk
por: Srivastava, Ankit, et al.
Publicado: (2019)

The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring
por: Olivier, J. D. A., et al.
Publicado: (2013)

Depression and the Use of Selective Serotonin Reuptake Inhibitors in Patients with Acute Intracerebral Hemorrhage
por: Syed, Maryam J, et al.
Publicado: (2019)

Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
por: Gök, Soner, et al.
Publicado: (2023)

A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
por: Zhong, Zhuoyuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_42jief8i2pqosr3rbi7433po2a